Compass Therapeutics (NASDAQ:CMPX) Price Target Raised to $24.00

Compass Therapeutics (NASDAQ:CMPX) had its price objective raised by equities research analysts at HC Wainwright from $10.00 to $24.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Several other research analysts have also recently weighed in on the stock. Guggenheim reissued a “buy” rating and issued a $12.00 price target on shares of Compass Therapeutics in a report on Wednesday. Wedbush reiterated an “outperform” rating and set a $8.00 target price on shares of Compass Therapeutics in a research note on Tuesday. Leerink Partnrs raised Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Leerink Partners upgraded Compass Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $4.00 to $6.00 in a research report on Wednesday. Finally, D. Boral Capital reissued a “buy” rating and issued a $32.00 target price on shares of Compass Therapeutics in a research report on Tuesday. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $13.38.

Compass Therapeutics Stock Down 5.0 %

Shares of NASDAQ CMPX opened at $1.61 on Friday. The business’s 50 day moving average price is $2.78 and its two-hundred day moving average price is $2.10. The company has a market cap of $221.94 million, a PE ratio of -4.34 and a beta of 1.19. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). As a group, research analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Trading of Compass Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Intech Investment Management LLC acquired a new position in Compass Therapeutics during the third quarter valued at approximately $30,000. Tower Research Capital LLC TRC raised its holdings in shares of Compass Therapeutics by 298.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after buying an additional 12,917 shares in the last quarter. Independent Advisor Alliance bought a new stake in shares of Compass Therapeutics during the 4th quarter worth $26,000. BNP Paribas Financial Markets acquired a new stake in Compass Therapeutics in the fourth quarter valued at about $27,000. Finally, XTX Topco Ltd acquired a new stake in Compass Therapeutics in the third quarter valued at about $37,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.